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ABSTRACT
Proteasome inhibitors and histone deacetylase (HDAC) inhibitors can 
synergistically induce apoptotic cell death in certain cancer cell types but their 
combinatorial effect on the induction of autophagy remains unknown. Here, we 
investigated the combinatorial effects of a proteasome inhibitor, bortezomib, and an 
HDAC inhibitor, romidepsin, on the induction of apoptotic and autophagic cell death 
in gastric carcinoma (GC) cells. Isobologram analysis showed that low nanomolar 
concentrations of bortezomib/romidepsin could synergistically induce killing of GC 
cells. The synergistic killing was due to the summative effect of caspase-dependent 
intrinsic apoptosis and caspase-independent autophagy. The autophagic cell death 
was dependent on the activation of MAPK family members (ERK1/2 and JNK), and 
generation of reactive oxygen species (ROS), but was independent of Epstein-Barr 
virus infection. In vivo, bortezomib/romidepsin also significantly induced apoptosis 
and autophagy in GC xenografts in nude mice. This is the first report demonstrating 
the potent effect of combination of HDAC and proteasome inhibitors on the induction 
of MAPK- and ROS-dependent autophagy in addition to caspase-dependent apoptosis 
in a cancer type.
INTRODUCTION
Gastric carcinoma (GC) is the second leading cause 
of cancer-related death in the world. The mortality is 
especially high in Russia, Korea and Japan. Surgery is the 
only curative treatment for early stage of GC. However, 
GC remains asymptomatic for a long period of time and 
thus more than half of the cases are diagnosed clinically 
with distant metastasis. For such metastatic cases, the 
diseases are largely incurable and the 5-year survival rate 
is less than 10% [1]. Cisplatin and 5-fluorouracil are the 
most common types of chemotherapy for metastatic GC. 
The only available targeted therapy is trastuzumab but 
its application is limited to the human epidermal growth 
factor receptor 2-positive patients [2]. There is a clear 
need to explore more potential therapeutic agents for the 
treatment of GC.
Histone deacetylase (HDAC) inhibitors represent a 
novel class of therapeutic agents for cancer treatment. The 
mechanisms of actions of HDAC inhibitors include up-
regulation of tumour suppressor genes, post-translational 
acetylation of histone and non-histone proteins and 
generation of reactive oxygen species (ROS) [3-5]. 
Activation of these mechanisms by HDAC inhibitors can 
lead to cell death through cell cycle arrest, senescence, 
apoptosis and autophagy [6-8]. Proteasome inhibitors are 
another emerging class of compounds for cancer treatment. 
It works by inhibiting the proteasomal degradation 
of ubiquitinated proteins which subsequently leads to 
apoptosis through induction of stress-related mechanisms 
in cancer cells [9, 10]. Recently, a couple of reports have 
shown that inhibition of proteasomal degradation by 
proteasome inhibitors can also induce autophagic cell 
death in cancer cells. For instance, a naturally occurring 
macrocyclic bisbibenzyl, Marchantin M, could non-
covalently bind to the active sites of proteasome B1 and 
B5 subunits, and induce autophagic cell death in prostate 
cancer cells [11]. A FDA-approved proteasome inhibitor, 
bortezomib, was also reported to induce autophagic cell 
death in several cancer cell lines through activation of 
AMP-activated protein kinase, caspase-8 or jun N-terminal 
kinase (JNK) [12-14].
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Our laboratory and others have reported that 
combination of proteasome and HDAC inhibitors can 
synergistically induce apoptosis of various types of 
cancer cells [15-20]. However, the combinatorial effect 
of proteasome and HDAC inhibitors on the induction 
of autophagy in cancer cells remains unexplored. GC 
cells were reported to be sensitive to both apoptotic and 
autophagic cell death [21, 22]. In this study, we aim to 
investigate the in vitro and in vivo effects of combining 
the FDA-approved proteasome inhibitor bortezomib with 
the FDA-approved HDAC inhibitor romidepsin on the 
induction of apoptosis and autophagy in GC cells. Our 
data showed that nanomolar concentrations of bortezomib/
romidepsin could synergistically kill GC cells through the 
induction of apoptosis and autophagy. The autophagic cell 
death was dependent on ROS generation and the activation 
of ERK1/2 and JNK pathways but was independent of 
the presence of Epstein-Barr virus (EBV). Furthermore, 
bortezomib/romidepsin could also significantly induce 
apoptosis and autophagy and suppress the growth of GC 
xenografts in nude mice. This is the first study which 
demonstrates that bortezomib/romidepsin can induce 
concomitant apoptotic and autophagic cell death in GC 
cells and provides novel insight into the mechanism 
of synergistic action between proteasome and HDAC 
inhibitors on the induction of autophagy in cancer cells.
RESULTS
Combination of proteasome and HDAC 
inhibitors (i.e. bortezomib/romidepsin) 
synergistically inhibited proliferation of GC cells
We tested whether the combination of bortezomib/
romidepsin could induce synergistic killing of GC cells 
in vitro. AGS-BDneo and SNU-719 cells were treated 
with various combinations of bortezomib (0, 3.75, 7.5 and 
15 nM) and romidepsin (0, 0.625, 1.25, 2.5, 5 and 10 nM) 
for 48 hr. The treated cells were assayed for percentage 
of cell proliferation by MTT assay. The drug combination 
yielded much stronger anti-proliferative effect when 
compared with either drug alone (Fig. 1a & 1d). The 
synergism between bortezomib/romidepsin was further 
analyzed by isobologram analysis (Fig. 1b & 1e). The 
isoboles lie to the left of the additive isoboles, indicating 
synergisms of bortezomib and romidepsin in their anti-
proliferative effects. Combination of 7.5 nM bortezomib 
and 2.5 nM romidepsin induced significantly stronger 
killing of GC cells when compared with either drug alone 
(P<0.001; Fig. 1c & 1f). The combination indices of AGS-
BDneo and SNU-719 cells treated with the combination 
of 7.5 nM bortezomib and 2.5 nM romidepsin are 0.134 
and 0.419, respectively. The low combination indices 
(both <1) further demonstrated the strong synergistic anti-
proliferative effects. The synergistic killing of GC cells 
could also be observed upon treatment with combinations 
of other HDAC and proteasome inhibitors (e.g. apicidin/
bortezomib or romidepsin/carfilzomib combinations) 
(Supplementary Fig. 1). On the other hand, bortezomib/
romidepsin did not induce synergistic killing of the normal 
human liver cell line MIHA, suggesting that the synergistic 
killing was specific to cancer cells (Supplementary Fig. 2).
Bortezomib/romidepsin induced apoptosis 
of GC cells
We then investigated whether the synergistic 
killing of GC cells by bortezomib/romidepsin was 
due to apoptosis. AGS-BDneo cells were treated with 
bortezomib, romidepsin or their combination for 24 and 48 
hr. The treated cells were assayed for apoptosis by annexin 
V/propidium iodide (AV/PI) staining. Bortezomib/
romidepsin treatment resulted in a higher percentage of 
apoptotic cells, when compared with either drug alone, 
in a time- and dose-dependent manner (Fig. 2a). At 48 
hr, the percentages of AV-positive populations upon 
treatment with 7.5 nM bortezomib, 2.5 nM romidepsin 
and bortezomib/romidepsin increased to 12%, 32% 
and 68%, respectively (Fig. 2b). To further analyze 
the kinetics of apoptosis, we analyzed the proteolytic 
cleavage of PARP, caspase-3, -8 and -9 in AGS-BDneo 
cells by western blotting and immunofluorescent staining. 
Cleavage of PARP and caspases was observed at an earlier 
time point (~12 hr) in the cells treated with bortezomib/
romidepsin when compared with those treated with either 
drug alone (Fig. 2c & 2d). The results suggested that the 
synergistic killing of GC cells was related to the induction 
of apoptosis.
The apoptosis induced by bortezomib/
romidepsin was dependent on a reactive oxygen 
species (ROS)- and caspase-dependent intrinsic 
pathway
We have reported that the combination of HDAC 
and proteasome inhibitors could induce apoptosis of 
nasopharyngeal carcinoma (NPC) cells through an ROS- 
and caspase-dependent mechanism [19, 20]. Here, we 
tested whether the synergistic killing of GC cells by 
bortezomib/romidepsin was dependent on ROS generation 
and caspase activation. We treated GC cells with either 
NAC, an ROS scavenger, or Z-VAD-FMK, a pan-caspase 
inhibitor before treatment with bortezomib/romidepsin. 
We found that both NAC and Z-VAD-FMK could 
significantly reduce the cleavage of PARP and caspase-3, 
-8 and -9 (Fig. 3a). Since the intrinsic apoptotic initiator 
caspase-9 was activated, we also performed the JC-1 assay 
to investigate whether bortezomib/romidepsin could affect 
the mitochondrial membrane potential in GC cells. Our 
data showed that the drug combination could effectively 
reduce the mitochondrial membrane potential when 
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compared with either drug alone (Fig. 3b). Moreover, we 
confirmed that bortezomib/romidepsin could also induce 
the generation of ROS in GC cells (Fig. 3c). Collectively, 
our data suggest that bortezomib/romidepsin could induce 
GC cell death through an ROS- and caspase-dependent 
intrinsic apoptotic pathway.
Bortezomib/romidepsin also induced caspase-
independent cell death
It is reported that GC is subject to both apoptotic 
and autophagic cell death upon treatment with different 
therapeutic agents [21, 22]. We thus also investigated 
the mediation of other cell death through mechanisms in 
addition to apoptosis by the combination. According to the 
active caspase-3/PI assay, although caspase-3 activation 
(Z-DEVD +ve cells) was detected in the majority of dead 
cells (PI +ve cells), addition of the pan-caspase inhibitor 
Z-VAD-FMK could only partially reduce the percentage 
of dead cells induced by bortezomib/romidepsin (Fig. 4). 
Furthermore, addition of necrostatin-1, an inhibitor of 
necroptosis, did not suppress the cell death by bortezomib/
romidepsin (Fig. 4). However, cell death was largely 
dependent on ROS generation because NAC significantly 
reduced the percentage of dead cells (Fig. 4). Taken 
together, our data indicated that a significant proportion of 
cells were killed through an ROS-dependent, but caspase-
independent pathway.
Bortezomib/romidepsin induced autophagic 
cell death
To investigate whether the caspase-independent cell 
death was mediated through autophagy, we examined the 
expression of several proteins known to be participated 
in the induction of autophagy, including LC3-I, LC3-II, 
Beclin-1 and ATG-12, in GC cells treated with bortezomib/
romidepsin (Fig. 5a). The expression of LC3-I, LC3-II and 
Atg-12 was up-regulated upon treatment with bortezomib/
romidepsin. The up-regulation of these proteins was 
significantly counteracted by the addition of NAC but not 
Z-VAD-FMK, indicating that the induction of autophagy 
was ROS-dependent but not caspase-dependent. To further 
Figure 1: Effects of combination of bortezomib/romidepsin on cell proliferation of GC cells. AGS-BDneo and SNU-719 cells 
were treated with various combinations of bortezomib/romidepsin for 48 hr. A & D. Data are presented as percentages of cell proliferation 
as determined by MTT assays. B & E. Synergisms of proliferation inhibition of the two cell lines were analyzed by isobologram analysis. 
C & F. Percentages of cell proliferation of GC cells upon treatment with combination of 7.5 nM bortezomib and 2.5 nM romidepsin were 
compared to those treated with either drug alone and combination indexes (CI) were calculated. Percentages of proliferating cells treated 
with bortezomib/romidepsin were compared with those untreated or treated with either drug alone using One-way ANOVA Dunnett’s 
Multiple Comparison Test. P value < 0.05 was considered statistically significant (***p < 0.001). Error bars represent the standard error of 
mean (SEM) of data obtained in at least three independent experiments.
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confirm that bortezomib/romidepsin induced autophagy in 
GC cells, we detected the expression of p62/SQSTM1, an 
important marker of autophagy, in AGS-BDneo and SNU-
719 cells upon treatment with bortezomib/romidepsin (BR) 
with or without chloroquine, an inhibitor of autophagic 
flux (Fig. 5b & 5c). We found that bortezomib/romidepsin 
induced the formation of p62/SQSTM1 protein aggregates 
in GC cells in the absence of chloroquine. The addition of 
chloroquine further increased the accumulation of the p62/
SQSTM1 protein aggregates, substantiating the induction 
of autophagic machinery in GC cells. To examine the role 
of autophagy in the killing of GC cells, we treated both 
AGS-BDneo and SNU-719 cells with 3-MA, an inhibitor 
of autophagosome formation, before treatment with 
bortezomib/romidepsin and assayed for the percentage of 
cell death by PI staining (Fig. 5d). Our data showed that 
3-MA could reduce ~20% (similar to the percentages of 
cells resistant to the treatment with Z-VAD-FMK; refer to 
Fig. 4) of cell death mediated by bortezomib/romidepsin, 
suggesting that the killing of GC cells was also related to 
the induction of autophagy.
The induction of autophagy by bortezomib/
romidepsin was dependent on generation of ROS 
and activation of ERK1/2 and JNK pathways
The induction of apoptosis and autophagy in 
cancer cells are known to be regulated by several 
mitogen-activated protein kinases (MAPKs) pathways, 
including the extracellular signal-regulated kinase 1/2 
(ERK1/2), c-Jun-NH2-terminal kinase (JNK) and p38 
MAPK pathways [13, 23-25]. We, therefore, analyzed 
the expression kinetics of the phosphorylated forms 
of ERK1/2, JNK and p38 MAPK in GC cells before 
and after treatment with bortezomib/romidepsin. The 
phosphorylation of ERK1/2 and JNK was increased at 
around 2-4 hr post-treatment, followed by the cleavage of 
PARP and LC3 at 12 hr post-treatment. Phosphorylation 
of p38 was not affected by the drug combination (Fig. 6a 
& 6b). To further evaluate the roles of these pathways in 
the induction of autophagy and apoptosis by bortezomib/
romidepsin, we investigated the cleavage of LC3 and 
caspase-3 in the GC cells following pharmacological 
inhibition of the MEK (upstream regulator of ERK1/2), 
Figure 2: Effects of bortezomib/romidepsin on apoptosis of GC cells. A. AGS-BDneo cells were treated with combination of 7.5 
nM bortezomib and either 1.25 or 2.5 nM romidepsin or either drug alone for 24 hr and 48 hr, respectively. The treated cells were assayed 
for apoptosis by annexin V/propidium iodide (AV/PI) staining. B. Percentages of apoptotic cells treated with bortezomib/romidepsin were 
compared with those untreated or treated with either drug alone using One-way ANOVA Dunnett’s Multiple Comparison Test. P value < 
0.05 was considered statistically significant (***p < 0.001). C. AGS-BDneo cells were treated with combination of 7.5 nM bortezomib 
and 2.5 nM romidepsin or either drug alone for 12, 24 and 48 hr followed by detection of expression of PARP, cleaved PARP and cleaved 
caspase-3, -8 and -9 by western blot analysis. α-tubulin served as loading control. D. AGS-BDneo cells were treated with combination 
of 7.5 nM bortezomib and 2.5 nM romidepsin or either drug alone for 24 hr. Expression of cleaved PARP (red signals) was detected by 
immunofluorescent staining. DAPI (blue signals) stained the cell nuclei. Scale bar, 100 μm.
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Figure 3: Roles of caspase activation and reactive oxygen species (ROS) generation in the apoptosis of GC cells induced 
by bortezomib/romidepsin. A. AGS-BDneo and SNU-719 cells were pre-treated with either 50 μM Z-VAD-FMK or 12 mM N-acetyl-
cystein (NAC) for 1 hr followed by treatment with combination of 7.5 nM bortezomib and 2.5 nM romidepsin or either drug alone for 
24 hr. The treated cells were analyzed for the expression of PARP, cleaved PARP, cleaved caspase-3, -8 and -9 and acetylated histone H4 by 
western blot analysis. α-tubulin served as loading control. B. Decreases in mitochondrial membrane potential in GC cells upon treatment 
with bortezomib/romidepsin for 48 hr were analyzed by JC-1 assay. C. Generation of ROS was detected by DCFH-DA staining.
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JNK or p38 MAPK pathways. Our data showed that the 
MEK inhibitor PD98059 and JNK inhibitor SP600125 
significantly reduced the cleavage of LC3-I to LC3-II but 
not the cleavage of caspase-3. However, the p38 MAPK 
inhibitor SB202190 did not affect the cleavage of both 
LC3 and caspase-3. As expected, phosphorylation of 
ERK1/2 and c-Jun, downstream signaling molecules of the 
MEK and JNK pathways was also significantly reduced by 
the MEK and JNK inhibitors (Fig. 6c & 6d). Consistently, 
pre-treatment with PD98059 and SP600125 also reduced 
the percentage of bortezomib/romidepsin-induced dead 
cells (Supplementary Fig. 3). Addition of NAC could 
significantly inhibit the phosphorylation of ERK1/2 
and c-Jun, indicating that the activation of ERK1/2 and 
JNK pathways was downstream of ROS generation 
(Fig. 6e & 6f). Taken together, these data showed that 
autophagy induction by bortezomib/romidepsin was 
dependent on the generation of ROS and activation of 
ERK1/2 and JNK pathways.
Induction of autophagy and apoptosis of GC by 
bortezomib/romidepsin was independent of the 
presence of Epstein-Barr virus (EBV)
Around 9% of GC is associated with EBV infection 
[26]. The expression of EBV latent and lytic proteins 
might affect the efficacy of the drug treatment [27-30]. 
We tested the effect of bortezomib/romidepsin on the 
parental EBV-negative AGS cells to examine whether 
there are any differential responses in the EBV-negative 
AGS cells when compared with the EBV-positive AGS-
BDneo cells. We treated the AGS cells with bortezomib/
romidepsin and analyzed the expression of PARP, cleaved 
caspase-3, cleaved caspase-9 and LC3-I/II in the cell 
lysates (Supplementary Fig. 4). Our data showed that 
the expression levels of both apoptotic and autophagic 
markers in the EBV-negative AGS cells were very similar 
to those observed in the EBV-positive AGS-BDneo cells 
upon treatment with bortezomib/romidepsin (refer to 
Fig. 3a & 5a). As the induction of EBV lytic cycle could 
lead to enhanced cell death in GC cells [31-33], we 
also analyzed the expression of EBV lytic proteins and 
replication of viral DNA upon treatment with bortezomib/
romidepsin and found that bortezomib could suppress 
the lytic cycle induced by romidepsin in GC cells 
(Supplementary Fig. S5). Collectively, these data indicated 
that the synergistic killing of GC cells by bortezomib/
romidepsin was likely independent of EBV.
Bortezomib/romidepsin induced apoptosis 
and autophagy and suppressed GC tumour 
growth in vivo
We also evaluated the in vivo anti-tumour effect of 
bortezomib/romidepsin on GC xenografts established in 
nude mice. SNU-719 cells were inoculated subcutaneously 
at the right flanks of nude mice. The mice (n=5) were 
either treated with DMSO (vehicle control), 60 μg/kg 
bortezomib (day1-5 per week), 375 μg/kg romidepsin 
(day 1&4 per week) or their combination over 4 weeks 
by intraperitoneal injection. The growth of tumours and 
weight of mice were measured twice weekly during 
the experimental period. When compared with either 
bortezomib or romidepsin alone, administration of their 
combination resulted in much stronger tumour growth 
suppression but did not reduce the weight of the nude mice 
(Fig. 7a & 7b). On day 22, the average tumour mass in the 
control group increased to ~700 mg. The average masses 
of tumours treated with either bortezomib or romidepsin 
alone increased to ~500 mg and ~450 mg, respectively, 
whilst those of the group treated with drug combination 
reduced to ~100 mg (Fig. 7c & 7d). Furthermore, 
bortezomib/romidepsin also induced expression of cleaved 
PARP, cleaved caspase-3, LC3-I/II, p-c-Jun and p-ERK1/2 
Figure 4: Percentages of caspase-dependent cell death induced by bortezomib/romidepsin in GC cells. AGS-BDneo and 
SNU-719 cells were pre-treated with either 50 μM Z-VAD-FMK, 12 mM NAC or 50 μM necrostatin-1 for 1 hr followed by treatment with 
combination of 7.5 nM bortezomib and 2.5 nM romidepsin or either drug alone for 72 hr. Percentages of active caspase-3-positive/death 
cells was analyzed by Z-DEVD-FMK/PI staining.
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in the tumours resected from the nude mice (Fig. 7e). 
The data suggest that the in vitro effect of bortezomib/
romidepsin on induction of apoptosis and autophagy could 
also be achieved in vivo.
DISCUSSION
Our laboratory and others have reported that 
combination of proteasome and HDAC inhibitors 
can synergistically induce the killing of various types 
of cancer cell lines through the induction of apoptosis 
[15-20]. However, the combinatorial effect of proteasome 
and HDAC inhibitors on the induction of autophagy 
remains unexplored. GC cells are sensitive to both 
apoptotic and autophagic cell death [21, 22]. In this 
study, we demonstrated that combination of a proteasome 
inhibitor, bortezomib, and a HDAC inhibitor, romidepsin, 
could potently induce the killing of GC cells through a 
mechanism involving the summative effect of the caspase-
dependent apoptosis and caspase-independent autophagy.
We analyzed the potential mechanisms of the 
induction of apoptosis and autophagy by combination 
Figure 5: Effects of bortezomib/romidepsin on induction of autophagy in GC cells. A. AGS-BDneo and SNU-719 cells pre-
treated with either 50 μM Z-VAD-FMK or 12 mM NAC for 1 hr and then treated with bortezomib/romidepsin for 24 hr were analyzed for 
the expression of PARP, cleaved PARP, LC3-I/II, Beclin-1 and Atg-12. α-tubulin served as loading control. B. AGS-BDneo or C. SNU-719 
cells were pre-treated with 10 μM chloroquine (CQ) for 1 hr followed by treatment with bortezomib/romidepsin (BR) for 24 hr. Expression 
of p62/SQSTM1 aggregates (green signal) was visualized with confocal microscopy. DAPI (blue signals) stained the cell nuclei. Scale bar, 
20 μm. D. GC cells were pre-treated with 5 mM 3-MA for 1 hr followed by treatment with bortezomib/romidepsin (combination) for 72 hr. 
Percentages of death cells were detected by PI staining.
Oncotarget4461www.impactjournals.com/oncotarget
Figure 6: The involvement of MAPK pathways in the induction of apoptosis and autophagy by bortezomib/romidepsin. 
A. AGS-BDneo and SNU-719 cells were treated with combination of 7.5 nM bortezomib and 2.5 nM romidepsin for 0, 2, 4, 8, 12 & 24 hr. 
The treated cells were analyzed for the expression of p-ERK1/2, p-JNK, p-p38, Beclin-1, LC3-I/II, PARP and cleaved PARP by western 
blot analysis. β-actin served as loading control. B. AGS-BDneo and SNU-719 cells were pre-treated with either 50 μM PD98059 (MEK 
inhibitor), 50 μM SP600125 (JNK inhibitor) and 20 μM SB202190 (p38 MAPK inhibitor) for 1 hr followed by treatment with combination 
of 7.5 nM bortezomib and 2.5 nM romidepsin or either drug alone for 24 hr. The treated cells were analyzed for the expression of p-ERK1/2, 
p-c-Jun, LC3-I/II and cleaved caspase-3 by western blot analysis. C. AGS-BDneo and SNU-719 cells were pre-treated with 12 mM NAC 
for 1 hr followed by treatment with combination of 7.5 nM bortezomib and 2.5 nM romidepsin or either drug alone for 8 hr. The expression 
of p-ERK1/2 and p-c-Jun was analyzed by western blot analysis. α-tubulin served as loading control.
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Figure 7: Effects of bortezomib/romidepsin on tumour growth suppression of GC xenografts in nude mice. SNU-719 
cells were subcutaneously injected into the right flanks of nude mice. When the tumours became palpable, the mice were either treated with 
60 μg/kg bortezomib (day1-5 per week), 375 μg/kg romidepsin (day 1&4 per week) or their combination for 4 weeks by intraperitoneal 
injection. A. The size of tumours during the period of experiment was measured twice weekly using a caliper. Data are presented as the 
mean tumour volumes of mice in both treatment and control groups on the days post-treatment. B. The weight of nude mice was measured 
every week. C. Picture showing the size of tumours at the end of the experiments D. Average tumour masses of mice of control and 
treatment groups were shown. The tumour volumes and masses of mice treated with bortezomib/romidepsin were compared with those 
treated with vehicle control (DMSO) or either drug alone using One-way ANOVA Dunnett’s Multiple Comparison Test. P value < 0.05 was 
considered statistically significant (***p < 0.001 and **p < 0.01). Error bars represent the standard error of mean (SEM) of tumour masses. 
E. Protein samples were extracted from the tumours and analyzed for the expression of PARP, cleaved PARP, cleaved caspase-3, LC3-I/II, 
p-c-Jun and p-ERK1/2 by western blotting. α-tubulin served as loading control.
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of bortezomib/romidepsin in GC cells [13, 23-25]. We 
found that the majority of cells were killed by an intrinsic 
caspase-dependent apoptotic pathway because bortezomib/
romidpesin induced the expression of active caspase-3 
and reduced mitochondrial membrane potential in a 
significant proportion of cells (refer to Fig. 3b & Fig. 4). 
In addition to the induction of apoptosis, a population of 
cells was resistant to the caspase-dependent cell death but 
was killed through the induction of autophagic cell death 
(refer to Fig. 4 & Fig. 5). Both apoptosis and autophagy 
induced by bortezomib/romidepsin were dependent on 
ROS generation since the addition of NAC significantly 
reduced the generation of ROS and abrogated the cleavage 
of PARP, caspases and LC3. Prior to the induction of 
apoptosis and autophagy, the phosphorylated MAPKs 
(p-ERK1/2 and p-JNK), the apoptotic cascades (caspase-3, 
-8 and -9), and the molecules for autophagosome 
formation (Beclin-1 and LC3-I/II), were up-regulated. 
We further showed that the induction of autophagic cell 
death was dependent on the ERK1/2 and JNK pathways 
since inhibition of these two pathways by their specific 
blockers significantly reduced the expression of LC3-
II and the percentage of dead cells. These findings are 
consistent with the reported roles of ERK1/2 and JNK 
pathways in the regulation of autophagic cell death in 
various types of cancer cells [23, 24]. Collectively, our 
data demonstrated that combination of proteasome and 
HDAC inhibitors (bortezomib/romidepsin) could induce 
concomitant apoptotic and autophagic cell death in GC 
cells through a mechanism involving the generation of 
ROS and activation of ERK1/2 and JNK pathways (refer 
to Supplementary Fig. 6).
Induction of autophagy can either be a pro-survival 
mechanism protecting cells against stress-induced killing 
[34-36] or a cell death mechanism induced by various 
anti-cancer agents [21, 22, 37-40]. Consistent with most of 
the reported data in other studies, our results showed that 
autophagic cell death induced by bortezomib/romidepsin 
was mediated through a strong production of ROS. 
We interpreted that the induction of autophagy will be 
cytoprotective when a moderate level of ROS is induced 
(e.g. under starvation). However, cell death mechanism 
would be activated if autophagy is induced through 
an acute increase of ROS in the cell. The disruption of 
lysosomes in cancer cells might be a possible mechanism 
of the autophagic cell death following strong production 
of ROS. It has been reported that acute generation of ROS 
can disrupt lysosomal membrane and lead to the leakage 
of hydrolytic enzymes which eventually cause cell death 
[41-43]. A recent report showed that induction of ROS 
generation by an anticancer agent, di-2-pyridylketone 
4,4-dimethyl-3-thiosemicarbazone, could prevent the 
fusion of lysosomes with autophagosomes and eventually 
lead to induction of autophagic cell death [44]. In fact, 
HDAC and proteasome inhibitors had also been reported 
to disrupt the lysosomes in head and neck squamous cell 
carcinoma and pancreatic carcinoma cell lines [45, 46]. 
The data presented in this study might provide the ground 
for further in-depth investigation into the roles of ROS 
generation and lysosome disruption in the regulation of 
autophagic cell death.
Epstein-Barr virus (EBV) is closely associated with 
several types of malignancies, including endemic Burkitt 
lymphoma (BL), NPC and GC [47, 48]. In different EBV-
associated malignancies, the virus expresses different 
latency patterns, namely type I, II, III or Wp-restricted 
latency [47, 48]. We have reported that combination of 
proteasome and HDAC inhibitors could synergistically 
inhibit the growth of Wp-restricted and latency III BL 
cells but not latency I BL cells [30]. These findings 
suggested that combination of proteasome and HDAC 
inhibitors could potentially target EBV in lymphoid 
cells of type III or Wp-restricted latency. However, we 
had shown that EBV-specific killing was not observed 
in latency II EBV-positive NPC cells by combination of 
proteasome and HDAC inhibitors [19, 20]. In the present 
study, we also compared the responses of the parental 
EBV-negative AGS and the EBV-positive AGS-BDneo 
GC cells, which exhibit EBV latency I pattern, to the 
treatment of bortezomib/romidepsin. Both EBV-negative 
and -positive GC cells were extremely sensitive to the 
induction of apoptosis and autophagy by bortezomib/
romidepsin, indicating that the synergistic killing was not 
related to the presence of EBV.
Locoregional control by radical surgical resection 
is the only curative treatment for GC but more than half 
of GC cases have metastatic tumours at diagnosis [1]. 
The prognosis of such cases is poor because current 
chemotherapy has very limited effect on the disease [2]. 
Interestingly, we found that combination of bortezomib/
romidepsin could induce apoptosis and autophagy of GC 
cells at concentrations (7.5 nM and 2.5 nM, respectively) 
much lower than the target therapeutic concentrations in 
patients’ plasma (3400 nM and 790 nM, respectively) 
[49, 50]. We further demonstrated that bortezomib/
romidepsin could effectively induce apoptosis and 
autophagy and suppress the growth of GC xenografts in 
nude mice, indicating that the in vitro synergistic action of 
bortezomib/romidepsin in GC cells could also be achieved 
in vivo.
In summary, bortezomib/romidepsin synergistically 
induced killing of GC cells in vitro and in vivo. The 
synergistic killing was due to the summative effect of 
caspase-dependent apoptosis and caspase-independent 
autophagy. The activation of ERK1/2 and JNK pathways, 
as well as the generation of ROS, were involved in the cell 
death mechanism. The research data support the testing 
of bortezomib/romidepsin as a potential therapeutic 
regimen for metastatic or recurrent GC and provide novel 
insight into the mechanism of synergistic action between 
proteasome and HDAC inhibitors in the induction of 
autophagic cell death of cancer cells.
Oncotarget4464www.impactjournals.com/oncotarget
MATERIALS AND METHODS
Cell lines and drug treatment
AGS and AGS-BDneo (gifts from Prof. L. Hutt-
Fletcher, Louisiana State University, USA) are Epstein-
Barr virus (EBV)-negative and recombinant EBV infected 
GC cell lines, respectively [51]. SNU-719 is a GC cell 
line containing native EBV genomes (purchased from 
the Korean Cell Line Bank) [52, 53]. To assay for cell 
death, GC cells grown to 70% confluence were treated 
with various combinations of bortezomib or carfilzomib 
(Selleck Chemicals, Houston, TX) and apicidin or 
romidepsin (Selleck Chemicals) for 24 or 48 hr. To inhibit 
ROS generation, caspase activation and autophagosome 
formation, cells were pre-treated with either 12 mM 
N-acetyl-cysteine (NAC; Sigma-Aldrich, St. Louis, MO), 
50 μM Z-VAD-FMK (Torcris Bioscience, Bristol, UK), 
50 μM necrostatin-1 or 5 mM 3-Methyladenine (Sigma-
Aldrich), respectively, for 1 hr before treatment with 
bortezomib/romidepsin. The MEK inhibitor PD98059, 
JNK inhibitor SP600125 and p38 MAPK inhibitor 
SB202190 were purchased from Calbiochem (San Diego, 
CA). AGS and AGS-BDneo cell lines were authenticated 
with an AmpF/STR Identifiler PCR Amplication Kit 
(Applied Biosystems, Foster City, CA), according to the 
manufacturer’s protocol in August 2011. The data were 
analyzed by GeneScan and GeneMapper™ ID Software 
(Applied Biosystems). The STR profiles were compared 
with DSMZ database. SNU-719 cell line was authenticated 
by the Korean Cell Line Bank.
MTT assay
GC cells were seeded in triplicates in 96-well plates 
and treated with various combinations of either bortezomib 
(0, 3.75, 7.5 and 15 nM) or carfilzomib (0, 6.25, 12.5 and 
25 μM) and either romidepsin (0, 0.625, 1.25, 2.5, 5 and 
10 nM) or apicidin (0, 0.16, 0.3, 0.625, 1.25 and 2.5 μM) for 
48 hr. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT; Invitrogen, Carlsbad, CA) assay was 
performed and percentage of cell proliferation was 
calculated as previously described [20, 28, 29].
Annexin V/propidium iodide (AV/PI) assay
GC cells were incubated with drugs for 24 or 48 
hr. Following the incubation, both floating and adherent 
cells were collected and washed once with phosphate 
buffered saline (PBS). Cells were stained with FITC-AV 
and PI (BD Pharmingen™, Heidelberg, Germany) and 
the percentage of AV/PI-positive cells was calculated as 
previously described [20, 28].
Immunocytochemistry
GC cells grown on cover slips coated with 0.1% 
gelatin were treated with drugs for 24 hr. Cells were fixed 
with acetone for 10 minutes at room temperature. The fixed 
cells were then stained with cleaved poly (ADP-ribose) 
polymerase (PARP) or p62/SQSTM1 rabbit polyclonal 
antibody (1:200; Cell Signaling Technology, Beverly, MA) 
overnight at 4°C. Expression of proteins was visualized with 
Alexa Fluor 488 F(ab’)2 fragment of goat anti-rabbit IgG 
antibody (1:500; Invitrogen) under fluorescent microscope 
or Carl Zeiss LSM 710 confocal microscope (Carl Zeiss, 
Germany). Nuclei of cells were stained with 4ʹ,6-diamidino-
2-phenylindole (DAPI) (Roche, Mannheim, Germany).
Western blot analysis
GC cells were treated with drugs for 12, 24 or 48 hr. 
Proteins from the cell cultures were extracted and western 
blot analysis was performed as described previously [29]. 
Apoptotic proteins were detected with the antibodies 
reported previously [28]. Histone acetylation was detected 
with acetyl-histone H4 rabbit polyclonal antibodies 
(1:2000; Millipore, Temecula, CA). Expression of 
autophagic proteins was detected with Beclin-1, Atg12 and 
LC3-I/II rabbit polyclonal antibodies, respectively (1:1000; 
Cell Signaling Technology). Expression of phosphorylated 
JNK1/2 isoforms, phosphorylated c-Jun, phosphorylated 
ERK1/2 and phosphorylated p38 was detected with p-JNK, 
p-c-Jun, p-ERK1/2 and p-p38 rabbit polyclonal antibodies, 
respectively (1:1000; Cell Signaling Technology). 
Expression of human α-tubulin was detected with α-tubulin 
antibody (1:5000; Sigma-Aldrich) as a loading control.
JC-1 assay
GC cells were treated with drugs for 48 hr. One 
million cells were collected and washed once with PBS. 
The cells with loss of mitochondrial membrane potential, 
which was reflected by decreased JC-1 red signal, were 
detected with Flow Cytometry Mitochondrial Membrane 
Potential Detection Kit (BD Biosciences) following 
the manufacturer’s instructions. The stained cells were 
detected by flow cytometry (LSRII, BD Biosciences). 
Data were analyzed by FlowJo software (Tree Star).
Dichlorofluoescein diacetate (DCFH-DA) assay
DCFH-DA (Sigma-Aldrich) assay was performed to 
analyze the intracellular reactive oxygen species (ROS) 
level. AGS-BDneo and SNU-719 cells were treated with 
bortezomib/romidepsin for 24 hr. The adherent cells were 
then stained with 2 μM DCFH-DA. The change of ROS 
level was measured by flow cytometry as previously 
described [20].
Active caspase-3 assay
GC cells were treated with drugs for 72 hr. The 
treated cells were collected and washed once with PBS. 
Activation of caspase (DEVD) and cell death (PI) were 
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detected with CaspaTag Caspase-3, -7 In Situ Assay 
Kit, Fluorescein (Millipore, Billerica, MA) following 
the manufacturer’s instructions. The stained cells were 
detected by flow cytometry (LSRII, BD Biosciences). 
Data were analyzed by FlowJo software (Tree Star).
Nude mice experiment
Female BALB/c nude (nu/nu) mice were purchased 
at 5-6 weeks of age from the Laboratory Animal Unit, The 
University of Hong Kong. SNU-719 (1 × 107) cells were 
re-suspended in 200 μl serum-free culture medium. The 
cells were subcutaneously injected at the right flanks of 
nude mice at 6-7 weeks of age. When the tumours became 
palpable, 60 μg/kg body weight of mice of bortezomib 
(day1-5 per week), 375 μg/kg romidepsin (day 1&4 per 
week) or their combination dissolved in DMSO in 10 μl 
was administered to the nude mice of the treatment groups 
(n=5) by intraperitoneal (IP) injection for 4 weeks. Equal 
volume of DMSO was administered to the nude mice 
of the control group (n=5). The size and weight of the 
tumours were measured as described previously [20, 28].
Quantitative PCR assay
AGS-BDneo cells were treated with bortezomib/
romidepsin for 72 hr. The EBV viral load was analyzed by 
quantitative PCR as described previously [29]. Data were 
determined by triplicate wells in a 96-well plate format.
Statistical analysis
In vitro experiments were performed in triplicate 
and repeated at least 3 times. Data were analyzed for 
statistical significance using One-way ANOVA Dunnett’s 
Multiple Comparison Test. P value < 0.05 was considered 
statistically significant. Synergism of bortezomib and 
romidepsin was analyzed with isobologram analysis and 
combination index (CI) calculation as described previously 
[20]. In the isobologram, the curves that lie under the 
additive isobole suggest synergism and vice versa [54]. 
The CI was calculated using the Chou and Talalay method 
using Microsoft Excel software [55]. CI<1, =1 and >1 
represent synergy, additive and antagonism, respectively. 
All statistical analyses were performed with GraphPad 
Prism Version 5.0 software.
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